Regeneron initiates dose escalation study of bispecific antibodies for Lupus Nephritis
Regeneron Pharmaceuticals is conducting a dose escalation study of bispecific antibodies in adult participants with Lupus Nephritis.
Asset / Drug
Drug and asset intelligence for Lupus Nephritis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.